{"id":"NCT01725217","sponsor":"Novartis Vaccines","briefTitle":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","officialTitle":"A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2012-11-12","resultsPosted":"2014-03-18","lastUpdate":"2023-04-28"},"enrollment":198,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]}],"arms":[{"label":"MenACWY-CRM","type":"EXPERIMENTAL"}],"summary":"To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.","primaryOutcome":{"measure":"Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination","timeFrame":"Day 29","effectByArm":[{"arm":"Overall (â‰¥2 Years)","deltaMin":85,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["Russia"]},"refs":{"pmids":["15276396"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Injection site pain","Headache","Injection site erythema","Malaise","Myalgia"]}}